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Abstract
Background and aims:  Platinum resistance has been one of the most important problems in the management of ovarian cancer. The effects 
of various chemotherapeutic agents are limited in patients with platinum resistance. Therefore, developing new anticancer drugs that can 
improve the effect of currently used cytostatics is critical. The current study investigated the effects of valproic acid (VPA) alone and in 
combination with cisplatin on ovarian cancer cells.
Methods: In this experimental study, the human ovarian cancer cell lines (A2780-S and A2780-CP) were grown in RPMI-1640 medium in 
appropriate culture conditions. The cells were treated with various concentrations of cisplatin (0.15-400 µg/mL) or VPA (10-2000 µg/mL) 
and were incubated for 24, 48, and 72 hours. Moreover, A2780 cells were co-treated with different concentrations of cisplatin and VPA for 
48 hours. Afterward, cell viability was investigated using MTT assay. GraphPad Prism statistical software was used for the data analysis and 
ANOVA and Duncan’s test were conducted.
Results: A dose- and time-dependent reduction was observed in cell viability following the treatment with cisplatin or VPA. Moreover, co-
treatment of the A2780 cells with cisplatin and VPA resulted in a significantly greater inhibition of cell viability compared to the treatment 
with either agent alone. 
Conclusion: Overall, it can be argued that VPA does not only cause inhibition of proliferation and induction of apoptosis in ovarian cancer 
cells but also helps to enhance the antiproliferative effects of cisplatin and results in the increased susceptibility to cisplatin in resistant 
cells. VPA may therefore be used to treat cancer in the future.
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Introduction
Ovarian cancer is one of the most prevalent cancers 
worldwide and the first leading cause of death as a 
reproductive system cancer among women (1). The 
mainstay of treatment of ovarian cancer is cytoreductive 
surgery followed by chemotherapy. Cisplatin and its 
derivatives are widely used as chemotherapeutic agents for 
the treatment of various cancers, including ovarian cancer 
(2,3). Accordingly, cisplatin and carboplatin are used for 
the treatment of ovarian cancer. Cisplatin, as an alkylating 
agent, binds to the N7-guanine to form intrastrand 
crosslink DNA adducts that can effectively prevent 
replication and transcription and induce apoptosis (4,5).
Despite its high therapeutic potential, cisplatin is not 
widely used to treat ovarian cancer due partly to reduced 
intracellular drug accumulation, increased platinum-DNA 
adduct repair, and enhanced platinum-DNA damage 
tolerance that lead to intense side effects and development 
of cisplatin resistance in cancer cells (2,6). Therefore, 
developing new anticancer drugs that can more specifically 
prevent the growth of ovarian cancer cells may improve 
the effect of currently used cytostatics and consequently 
increase survival rate, which is considered a critical issue 
in patients (6-8).
Valproic acid (VPA), a branched short-chain fatty acid, 
is mainly used to treat epilepsy and bipolar disorders. 
Recently, VPA has been widely studied for its anti-cancer 
effects in many cancers (9-11). In this regard, VPA induces 
cell cycle arrest, apoptosis, differentiation, and senescence. 
Moreover, it has been observed that VPA arrests tumor 
growth and increases the susceptibility of cancer cells to 
the therapeutic agents (12,13). VPA exerts few toxic side 
effects and often is used as an adjuvant in combination 
with anticancer cytotoxic drugs. Therefore, the aim of this 
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study was to investigate the anti-cancer activity of VPA 
in two ovarian cancer cell lines, A2780-S and A2780-CP, 
alone and in combination with cisplatin.
Materials and Methods
Cell culture reagents, including RPMI-1640 culture 
medium, penicillin-streptomycin, trypsin-EDTA, 
phosphate buffered saline (PBS), and fetal bovine serum 
(FBS) were purchased from Gibco Co. (Invitrogen, 
Carlsbad, CA, USA). MTT (3-(4, 5-dimethylthiazol-2-
yl)-2, 5-diphenyltetrazolium bromide) assay kit was also 
provided from BIO IDEA Co. (Tehran-Iran). Cisplatin 
and VPA were purchased from Sigma-Aldrich (St. Louis, 
MO, USA). Moreover, a stock solution of cisplatin (500 
µM) and VPA (60 mM) was prepared in PBS immediately 
before use.
Furthermore, the human ovarian cancer cell lines 
(A2780-S and A2780-CP) were obtained from the 
National Cell Bank of Iran (NCBI), Pasteur Institute 
of Iran (NCBI, C461 and C454). A2780 cells were 
grown in RPMI-1640 supplemented with 10% FBS 
and 1% penicillin/streptomycin incubated at 37°C with 
humidified air and 5% CO2.
The viability of A2780 cells was measured by the MTT 
assay after the treatment with cisplatin, VPA, and their 
combination. Briefly, cancer cells were seeded into a 96-
well plate at 8000 cells/mL (A2780-CP) and 4000 cells/
mL (A2780-S) densities and incubated overnight. Next, 
the medium was discarded and the cells were treated with 
serial dilutions of either VPA or cisplatin in a fresh culture 
medium for 24, 48, and 72 hours. All concentrations were 
replicated 3-4 times. The cells that were left untreated 
were considered control. After the incubation, medium 
was removed, and 10 µL of MTT in 100 µL fresh medium 
was added to each well and incubated at 37°C for 4 
hours. The medium with MTT was removed and MTT 
formazan crystals were solubilized in 150 µL of DMSO, 
and absorbance of each well was measured at 570 nm 
using an ELISA reader (AWARENESS-State Fax, USA). 
The rate of cell viability was determined by the following 
formula (14):
Cell viability rate (%) = OD of treated cells/OD of control 
cells × 100
Each experiment was performed at least in triplicate. 
GraphPad Prism statistical software, version 5.01 
(GraphPad, USA) was used for the data analysis, and 
analysis of variance (ANOVA) and Duncan’s test were 
conducted. All data were presented as mean ± standard 
deviation (SD). P < 0.05 was considered statistically 
significant.
Results 
In this stydy, the effect of cisplatin was investigated on two 
ovarian cancer cell lines, namely A2780-S and A2780-
CP, at different time points (24, 48, and 72 hours). Our 
results showed that IC50 values in A2780-S cells at the 
abovementioned time points were 6.5, 1.4, and 0.67 µg/
mL, respectively. Moreover, the IC50 values of cisplatin 
in A2780-CP cells were observed 25, 2.8, and 1.5 µg/mL 
at 24, 48, and 72 hours, respectively (Table 1, Figure 1).
Furthermore, the effect of VPA on A2780-S cells in 
different time points was examined. Our results showed 
a dose-dependent decrease in cell viability, suggesting that 
A2780-CP cells were more sensitive to VPA treatment 
(IC50 values = 1000, 400, 275 µg/mL) than A2780-S cells 
(IC50 values= 1200, 650, 425 µg/mL) in different time 
points (Figure 2, Table 1).
In addition, the investigation of A2780-S cells under 
different concentrations of cisplatin and VPA for 48 hours 
showed a more significant reduction of cell viability in 
combination therapy compared to monotherapy. The 
IC50 values were 0.12 and 1.2 µg/mL for cisplatin in 
A2780-S cells and A2780-CP cells, respectively. While, 
the IC50 of VPA was 400 µg /mL in A2780-S cells and 
100 µg /mL in A2780-CP cells (Figure 3).
Discussion
The present study showed the effect of VPA (a histone-
deacetylase inhibitor) on cisplatin-resistant ovarian 
cancer cell lines. Cisplatin is one of the most important 
anticancer compounds used in the first line of 
chemotherapy for the treatment of ovarian cancer (15). 
Resistance to chemotherapeuic drugs including cisplatin, 
is a hindrance to successful chemotherapy in the patients 
with ovarian cancer (16,17). Therefor, new modalities 
are needed to overcome drug resistance (17,18). VPA is 
a short chain fatty acid which is used in the treatment of 
various neurological disorders including seizures, bipolar 
disorder, and migraine (19). Recent studies have shown 
the anticancer effects of VPA (20, 21). In this study, first, 
the antiproliferative effects of cisplatin and VPA were 
compared at different time points and concentrations 
on two cell lines, A2780-S and A2780-CP, by the MTT 
assay. Then, different concentrations of both drugs were 
prepared to investigate the sensitizing effect of VPA on 
resistance to cisplatin. 
The treatment of two cell lines of A2780-S and A2780-
CP with cisplatin and VPA at different time points (24, 
48, and 72 hours) indicated that the rate of cell viability 
was reduced in a time-dependent manner. The effect of 
Table 1. IC50 of Cisplatin and VPA at Different Time Points
A2780-S (µg/mL) A2780-CP(µg/mL)
Cisplatin (24 h) 6.5 25
Cisplatin (48 h) 1.4 2.8
Cisplatin (72 h) 0.67 1.5
VPA (24 h) 1200 1000
VPA (48 h) 650 400
VPA (72 h) 425 275
                                                          Journal of Shahrekord University of Medical Sciences, Volume 21, Issue 1, 2019 41
VPA effect on cisplatin-resistant cancer cell lines
different concentrations of cisplatin was also assessed, the 
results of which showed a dose-dependent decrease in the 
cell viability. Cisplatin alone led to a significant reduction 
in cell survival at 0.15 µg/mL for A2780-S and 0.3 µg/mL 
for A2780-CP (Figures 1E, and 1D). A dose-dependent 
reduction in cell viability was also observed following the 
treatment with VPA. The lowest concentration of VPA 
that inhibited the cell growth was 10 µg/mL for both 
A2780-S and A2780CP cells, whereas 2000 µg/mL of VPA 
abolished ovarian cancer cells almost completely (Figure 
2). Although cisplatin treatment resulted in a further 
reduction in A2780-S cell viability at 24, 48, and 72 hours 
(The IC50 values of cisplatin for A2780-S were 6.5, 1.4, 
0.67 µg/mL and for A2780-CP were 25, 2.8, 1.5 µg/mL, 
respectively) (Figure 1) ,we observed that A2780-CP cells 
were more sensitive to VPA treatment than A2780-S cells 
(The IC50 values of VPA for A2780-S were 1000, 400, 
275 µg/mL and for A2780-CP were 1200, 650, 425 µg/
mL, respectively) (Figure 2). 
Furthermore, co-treatment of the A2780 cells with 
cisplatin and VPA for 48 hours resulted in a significantly 
greater inhibition of cell viability compared to the 
treatment with either agent alone. The co-treatment of 
A2780-S cells with 400 µg/mL VPA and 0.12 µg/mL 
cisplatin suppressed cell growth by 50%. Moreover, the 
treatment of A2780-CP cells with the combination of 100 
µg/mL VPA and 1.2 µg/mL cisplatin decreased cell growth 
by 50% (Figure 3). Our results showed that VPA could 
sensitize even the drug-resistant cell lines and cause the 
inhibition of cell viability. 
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Figure 1. Growth of A2780-S and A22780-CP cells cultured in the presence of various concentrations of cisplatin after 24 (A, B), 48 (C, D), and 72 hours (E, F). 
Each bar represents the mean ± standard deviation; P < 0.05.
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The findings of MTT assay regarding the effect of 
cisplatin in inhibiting the growth of A2780 cancer cells 
demonstrated that certain concentrations of this drug 
could significantly inhibit the growth of cancer cells, to 
such a degree that higher concentrations of cisplatin had 
a higher ability to kill the cells. Given that most routinely 
used chemotherapy drugs are cytotoxic, they may damage 
normal cells of the body and cause adverse side effects (20). 
A strategy to resolve this problem is the use of chemotherapy 
drugs alongside the drugs already approved for treating 
non-cancer diseases with widely known toxicity. A group 
of these drugs are anticonvulsants including VPA. VPA 
has attracted much attention due to its inhibitory effects 
on the proliferation, invasion, migration, and angiogenesis 
of cancer cells (22). The present study demonstrated that 
VPA could decrease the viability of ovarian cancer cells in 
a dose-dependent manner. The antiproliferative activity of 
VPA has already been confirmed on a wide spectrum of 
cell lines including leukemia (23), melanoma (24), lung 
cancer (25), breast cancer (26), prostate cancer (27), and 
gastric carcinoma (28). 
Besides, VPA renders the improvement of efficacy of 
chemotherapy drugs such as cisplatin. Likewise, in the 
present study, VPA enhanced the cisplatin-induced growth 
inhibitory effect in the cells under this study. The results of 
MTT assay indicated that co-treatment of ovarian cancer 
cells with VPA and cisplatin caused a decrease in the 
cisplatin concentration required to reach the IC50. When 
VPA and cisplatin are used simultaneously, cell death 
increases particularly in the cisplatin-resistant cell lines. 
This suggests that VPA may increase the susceptibility of 
ovarian cancer cells to induce apoptosis. The findings on 
the effect of combined cisplatin and VPA on melanoma 
(15) and larynx (29) cancer cell lines are consistent with 
the results of our study.
Conclusion
According to the findings of this study, it can be argued 
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Figure 2. Growth of A2780-S and A22780-CP cells Cultured in the Presence of Various Concentrations of VPA After 24 (A, B), 48 (C, D), and 72 hours (E, F). Each 
bar represents the mean ± standard deviation; P < 0.05.
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that VPA can cause the inhibition of proliferation and 
induction of cell death in A2780 cancer cell lines. The 
antiproliferative activity is also dose- and time- dependent. 
Moreover, VPA can enhance the antiproliferative effects 
of cisplatin, and result in the increased susceptibility in 
the cisplatin-resistant cells. Taken together, the findings 
support that treatment with VPA can lead to an increased 
susceptibility to cisplatin in ovarian cancer cells and 
enhance the efficacy of chemotherapeutic agents. VPA 
can be therefore recommended as a useful drug in cancer 
therapy. However, further studies are required to determine 
the precise rate of apoptosis using qualitative techniques 
such as flow cytometry.
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